"MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs."


The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?...
www.ncbi.nlm.nih.gov
Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24.